Infect Chemother.  2017 Dec;49(4):301-325. 10.3947/ic.2017.49.4.301.

Clinical Guidelines for the Antibiotic Treatment for Community-Acquired Skin and Soft Tissue Infection

Affiliations
  • 1The Korean Society of Infectious Diseases, Seoul, Korea.
  • 2Department of Internal Medicine, Inje University Ilsan Paik Hospital, Goyang, Korea. sangho@amc.seoul.kr
  • 3The Korean Society for Chemotherapy, Seoul, Korea.
  • 4Department of Internal Medicine, Chung Ang University College of Medicine, Seoul, Korea.
  • 5Department of Internal Medicne, SoonChunHyang University Bucheon Hospital, Buchon, Korea.
  • 6Department of Internal Medicine, Dongguk University College of Medicine, Goyang, Korea.
  • 7The Korean Dermatological Association, Seoul, Korea.
  • 8Department of Dermatology, Korea University College of Medicine, Seoul, Korea.
  • 9The Korean Orthopaedic Association, Seoul, Korea.
  • 10Department of Orthopedic Surgery, Seoul National University College of Medicine, Seoul, Korea.
  • 11Department of Infectious Diseases, Ulsan University College of Medicine, Seoul, Korea.

Abstract

Skin and soft tissue infection (SSTI) is common and important infectious disease. This work represents an update to 2012 Korean guideline for SSTI. The present guideline was developed by the adaptation method. This clinical guideline provides recommendations for the diagnosis and management of SSTI, including impetigo/ecthyma, purulent skin and soft tissue infection, erysipelas and cellulitis, necrotizing fasciitis, pyomyositis, clostridial myonecrosis, and human/animal bite. This guideline targets community-acquired skin and soft tissue infection occurring among adult patients aged 16 years and older. Diabetic foot infection, surgery-related infection, and infections in immunocompromised patients were not included in this guideline.

Keyword

Impetigo; Erysipelas; Cellulitis; Fasciitis; Pyomyositis

MeSH Terms

Adult
Cellulitis
Communicable Diseases
Diabetic Foot
Diagnosis
Erysipelas
Fasciitis
Fasciitis, Necrotizing
Humans
Immunocompromised Host
Impetigo
Methods
Pyomyositis
Skin*
Soft Tissue Infections*

Figure

  • Figure 1 Selection of practice guidelines assessed


Cited by  3 articles

A Case of Bergeyella zoohelcum Isolated from a Patient with Cellulitis after a Dog Bite
Kiwook Jung, Jae Hyeon Park, Chang Kyung Kang, Taek Soo Kim, Hyunwoong Park
Lab Med Online. 2020;11(1):73-77.    doi: 10.47429/lmo.2021.11.1.73.

Principles of selecting appropriate antimicrobial agents
Su-Mi Choi, Dong-Gun Lee
J Korean Med Assoc. 2019;62(6):335-344.    doi: 10.5124/jkma.2019.62.6.335.

Microbiology and Antimicrobial Therapy for Diabetic Foot Infections
Ki Tae Kwon, David G. Armstrong
Infect Chemother. 2018;50(1):11-20.    doi: 10.3947/ic.2018.50.1.11.


Reference

1. May AK, Stafford RE, Bulger EM, Heffernan D, Guillamondegui O, Bochicchio G, Eachempati SR; Surgical Infection Society. Treatment of complicated skin and soft tissue infections. Surg Infect (Larchmt). 2009; 10:467–499.
Article
2. Esposito S, Bassetti M, Borre’ S, Bouza E, Dryden M, Fantoni M, Gould IM, Leoncini F, Leone S, Milkovich G, Nathwani D, Segreti J, Sganga G, Unal S, Venditti M; Italian Society of Infectious Tropical Diseases. International Society of Chemotherapy. Diagnosis and management of skin and soft-tissue infections (SSTI): a literature review and consensus statement on behalf of the Italian Society of Infectious Diseases and International Society of Chemotherapy. J Chemother. 2011; 23:251–262.
Article
3. The Korean Society of Infectious Diseases, The Korean Society for Chemotherapy, The Korean Orthopaedic Association, The Korean Society of Clinical Microbiology, The Korean Dermatologic Association. Clinical practice guidelines for soft tissue infections. Infect Chemother. 2012; 44:213–232.
4. Stevens DL, Bisno AL, Chambers HF, Dellinger EP, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan SL, Montoya JG, Wade JC; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. Clin Infect Dis. 2014; 59:e10–e52.
Article
5. Sartelli M, Malangoni MA, May AK, Viale P, Kao LS, Catena F, Ansaloni L, Moore EE, Moore FA, Peitzman AB, Coimbra R, Leppaniemi A, Kluger Y, Biffl W, Koike K, Girardis M, Ordonez CA, Tavola M, Cainzos M, Di Saverio S, Fraga GP, Gerych I, Kelly MD, Taviloglu K, Wani I, Marwah S, Bala M, Ghnnam W, Shaikh N, Chiara O, Faro MP Jr, Pereira GA Jr, Gomes CA, Coccolini F, Tranà C, Corbella D, Brambillasca P, Cui Y, Segovia Lohse HA, Khokha V, Kok KY, Hong SK, Yuan KC. World Society of Emergency Surgery (WSES) guidelines for management of skin and soft tissue infections. World J Emerg Surg. 2014; 9:57.
Article
6. Japanese Society of Chemotherapy Committee on guidelines for treatment of anaerobic infections; Japanese Association of Anaerobic Infections Research. Chapter 2-5-3a. Anaerobic infections (individual fields): skin and soft tissue infections. J Infect Chemother. 2011; 17:Suppl 1. 72–76.
7. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ; GRADE Working Group. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008; 336:924–926.
Article
8. Pasternack MS, Swartz MN. Cellulitis, necrotizing fasciitis, and subcutaneous tissue infections. In : Bennett JE, Dolin R, Blaser MJ, editors. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 8th ed. Philadelphia, PA: Churchill Livingstone;2015. p. 1194–1215.
9. Durupt F, Mayor L, Bes M, Reverdy ME, Vandenesch F, Thomas L, Etienne J. Prevalence of Staphylococcus aureus toxins and nasal carriage in furuncles and impetigo. Br J Dermatol. 2007; 157:1161–1167.
Article
10. Hirschmann JV. Impetigo: etiology and therapy. Curr Clin Top Infect Dis. 2002; 42–51.
11. Koning S, van der Wouden JC, Chosidow O, Twynholm M, Singh KP, Scangarella N, Oranje AP. Efficacy and safety of retapamulin ointment as treatment of impetigo: randomized double‐blind multicentre placebo‐controlled trial. Br J Dermatol. 2008; 158:1077–1082.
Article
12. Koning S, van der Sande R, Verhagen AP, van Suijlekom-Smit LW, Morris AD, Butler CC, Berger M, van der Wouden JC. Interventions for impetigo. Cochrane Database Syst Rev. 2012; 1:CD003261.
Article
13. Wasserzug O, Valinsky L, Klement E, Bar-Zeev Y, Davidovitch N, Orr N, Korenman Z, Kayouf R, Sela T, Ambar R, Derazne E, Dagan R, Zarka S. A cluster of ecthyma outbreaks caused by a single clone of invasive and highly infective Streptococcus pyogenes. Clin Infect Dis. 2009; 48:1213–1219.
Article
14. Bae EY, Lee JD, Cho SH. Isolation of causative microorganism and antimicrobial susceptibility in impetigo. Korean J Dermatol. 2003; 41:1278–1285.
15. Kim WJ, Lee KR, Lee SE, Lee HJ, Yoon MS. Isolation of the causative microorganism and antimicrobial susceptibility of impetigo. Korean J Dermatol. 2012; 50:788–794.
16. Moran GJ, Krishnadasan A, Gorwitz RJ, Fosheim GE, McDougal LK, Carey RB, Talan DA. EMERGEncy ID Net Study Group. Methicillin-resistant S. aureus infections among patients in the emergency department. N Engl J Med. 2006; 355:666–674.
Article
17. Rahimian J, Khan R, LaScalea KA. Does nasal colonization or mupirocin treatment affect recurrence of methicillin-resistant Staphylococcus aureus skin and skin structure infections? Infect Control Hosp Epidemiol. 2007; 28:1415–1416.
Article
18. Ellis MW, Griffith ME, Dooley DP, McLean JC, Jorgensen JH, Patterson JE, Davis KA, Hawley JS, Regules JA, Rivard RG, Gray PJ, Ceremuga JM, Dejoseph MA, Hospenthal DR. Targeted intranasal mupirocin to prevent colonization and infection by community-associated methicillin-resistant Staphylococcus aureus strains in soldiers: a cluster randomized controlled trial. Antimicrob Agents Chemother. 2007; 51:3591–3598.
Article
19. Whitman TJ, Herlihy RK, Schlett CD, Murray PR, Grandits GA, Ganesan A, Brown M, Mancuso JD, Adams WB, Tribble DR. Chlorhexidine-impregnated cloths to prevent skin and soft-tissue infection in Marine recruits: a cluster-randomized, double-blind, controlled effectiveness trial. Infect Control Hosp Epidemiol. 2010; 31:1207–1215.
Article
20. Wiese-Posselt M, Heuck D, Draeger A, Mielke M, Witte W, Ammon A, Hamouda O. Successful termination of a furunculosis outbreak due to lukS-lukF–positive, methicillin-susceptible Staphylococcus aureus in a German village by stringent decolonization, 2002-2005. Clin Infect Dis. 2007; 44:e88–e95.
Article
21. Fritz SA, Hogan PG, Hayek G, Eisenstein KA, Rodriguez M, Epplin EK, Garbutt J, Fraser VJ. Household versus individual approaches to eradication of community-associated Staphylococcus aureus in children: a randomized trial. Clin Infect Dis. 2011; 54:743–751.
Article
22. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med. 1996; 334:240–245.
Article
23. Perl B, Gottehrer NP, Raveh D, Schlesinger Y, Rudensky B, Yinnon AM. Cost-effectiveness of blood cultures for adult patients with cellulitis. Clin Infect Dis. 1999; 29:1483–1488.
Article
24. Hook EW 3rd, Hooton TM, Horton CA, Coyle MB, Ramsey PG, Turck M. Microbiologic evaluation of cutaneous cellulitis in adults. Arch Intern Med. 1986; 146:295–297.
Article
25. Kielhofner MA, Brown B, Dall L. Influence of underlying disease process on the utility of cellulitis needle aspirates. Arch Intern Med. 1988; 148:2451–2452.
Article
26. Duvanel T, Auckenthaler R, Rohner P, Harms M, Saurat JH. Quantitative cultures of biopsy specimens from cutaneous cellulitis. Arch Intern Med. 1989; 149:293–296.
Article
27. Eriksson B, Jorup-Rönström C, Karkkonen K, Sjöblom AC, Holm SE. Erysipelas: clinical and bacteriologic spectrum and serological aspects. Clin Infect Dis. 1996; 23:1091–1098.
Article
28. Kwak YG, Kim NJ, Choi SH, Choi SH, Chung JW, Choo EJ, Kim KH, Yun NR, Lee S, Kwon KT, Cho JH. Clinical characteristics and organisms causing erysipelas and cellulitis. Infect Chemother. 2012; 44:45–50.
Article
29. Stevens DL, Bisno AL, Chambers HF, Everett ED, Dellinger P, Goldstein EJ, Gorbach SL, Hirschmann JV, Kaplan EL, Montoya JG, Wade JC; Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005; 41:1373–1406.
Article
30. Bernard P, Bedane C, Mounier M, Denis F, Catanzano G, Bonnetblanc JM. Streptococcal cause of erysipelas and cellulitis in adults. A microbiologic study using a direct immunofluorescence technique. Arch Dermatol. 1989; 125:779–782.
Article
31. Park SY, Kim T, Choi SH. Jung J, Yu SN, Hong H-L, Kim YK, Park SY, Song EH, Park K-H, Cho OH, Choi SH, Kwak YG, and the Korean SSTI (Skin and Soft Tissue Infection) Study Group. A multicenter study of clinical features and organisms causing community-onset cellulitis in Korea. [abstract]. Int J Antimicrob Agents. 2017; 50:Suppl 1. S75.
32. Chan JC. Ampicillin/sulbactam versus cefazolin or cefoxitin in the treatment of skin and skin-structure infections of bacterial etiology. Adv Ther. 1995; 12:139–146.
33. Jeng A, Beheshti M, Li J, Nathan R. The role of beta-hemolytic streptococci in causing diffuse, nonculturable cellulitis: a prospective investigation. Medicine (Baltimore). 2010; 89:217–226.
Article
34. Hepburn MJ, Dooley DP, Skidmore PJ, Ellis MW, Starnes WF, Hasewinkle WC. Comparison of short-course (5 days) and standard (10 days) treatment for uncomplicated cellulitis. Arch Intern Med. 2004; 164:1669–1674.
Article
35. Dupuy A, Benchikhi H, Roujeau JC, Bernard P, Vaillant L, Chosidow O, Sassolas B, Guillaume JC, Grob JJ, Bastuji-Garin S. Risk factors for erysipelas of the leg (cellulitis): case-control study. BMJ. 1999; 318:1591–1594.
Article
36. Björnsdóttir S, Gottfredsson M, Thórisdóttir AS, Gunnarsson GB, Ríkardsdóttir H, Kristjánsson M, Hilmarsdóttir I. Risk factors for acute cellulitis of the lower limb: a prospective case-control study. Clin Infect Dis. 2005; 41:1416–1422.
Article
37. Jorup-Rönström C, Britton S. Recurrent erysipelas: predisposing factors and costs of prophylaxis. Infection. 1987; 15:105–106.
Article
38. McNamara DR, Tleyjeh IM, Berbari EF, Lahr BD, Martinez J, Mirzoyev SA, Baddour LM. A predictive model of recurrent lower extremity cellulitis in a population-based cohort. Arch Intern Med. 2007; 167:709–715.
Article
39. Lewis SD, Peter GS, Gómez-Marín O, Bisno AL. Risk factors for recurrent lower extremity cellulitis in a U.S. Veterans Medical Center population. Am J Med Sci. 2006; 332:304–307.
Article
40. Karppelin M, Siljander T, Vuopio-Varkila J, Kere J, Huhtala H, Vuento R, Jussila T, Syrjänen J. Factors predisposing to acute and recurrent bacterial non-necrotizing cellulitis in hospitalized patients: a prospective case-control study. Clin Microbiol Infect. 2010; 16:729–734.
Article
41. Pavlotsky F, Amrani S, Trau H. Recurrent erysipelas: risk factors. J Dtsch Dermatol Ges. 2004; 2:89–95.
42. Sjöblom AC, Eriksson B, Jorup-Rönström C, Karkkonen K, Lindqvist M. Antibiotic prophylaxis in recurrent erysipelas. Infection. 1993; 21:390–393.
Article
43. Kremer M, Zuckerman R, Avraham Z, Raz R. Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections. J Infect. 1991; 22:37–40.
Article
44. UK Dermatology Clinical Trials Network's PATCH Trial Team. Thomas K, Crook A, Foster K, Mason J, Chalmers J, Bourke J, Ferguson A, Level N, Nunn A, Williams H. Prophylactic antibiotics for the prevention of cellulitis (erysipelas) of the leg: results of the UK Dermatology Clinical Trials Network's PATCH II trial. Br J Dermatol. 2012; 166:169–178.
45. Thomas KS, Crook AM, Nunn AJ, Foster KA, Mason JM, Chalmers JR, Nasr IS, Brindle RJ, English J, Meredith SK, Reynolds NJ, de Berker D, Mortimer PS, Williams HC. U.K. Dermatology Clinical Trials Network's PATCH I Trial Team. Penicillin to prevent recurrent leg cellulitis. N Engl J Med. 2013; 368:1695–1703.
46. Wang JH, Liu YC, Cheng DL, Yen MY, Chen YS, Wang JH, Wann SR, Lin HH. Role of benzathine penicillin G in prophylaxis for recurrent streptococcal cellulitis of the lower legs. Clin Infect Dis. 1997; 25:685–689.
Article
47. Choi SH, Choi SH, Kwak YG, Chung JW, Choo EJ, Kim KH, Yun NR, Lee S, Kwon KT, Cho JH, Kim NJ. Clinical characteristics and causative organisms of community-acquired necrotizing fasciitis. Infect Chemother. 2012; 44:180–184.
Article
48. Kim T, Park SY, Gwak YG, Choi SH. Jung J, You SN, Hong H-L, Kim YK, Park SY, Song EH, Park K-H, Cho OH, Choi SH, and the Korean SSTI (Skin and Soft Tissue Infection) Study Group. A multicenter study of clinical characteristics and microbial etiology in commmunity-onset necrotizing fasciitis in Korea. [abstract]. Int J Antimicrob Agents. 2017; 50:Suppl 1. S136.
49. Wang YS, Wong CH, Tay YK. Staging of necrotizing fasciitis based on the evolving cutaneous features. Int J Dermatol. 2007; 46:1036–1041.
Article
50. Schmid MR, Kossmann T, Duewell S. Differentiation of necrotizing fasciitis and cellulitis using MR imaging. AJR Am J Roentgenol. 1998; 170:615–620.
Article
51. Becker M, Zbären P, Hermans R, Becker CD, Marchal F, Kurt AM, Marré S, Rüfenacht DA, Terrier F. Necrotizing fasciitis of the head and neck: role of CT in diagnosis and management. Radiology. 1997; 202:471–476.
Article
52. Arslan A, Pierre-Jerome C, Borthne A. Necrotizing fasciitis: unreliable MRI findings in the preoperative diagnosis. Eur J Radiol. 2000; 36:139–143.
Article
53. Kao LS, Lew DF, Arab SN, Todd SR, Awad SS, Carrick MM, Corneille MG, Lally KP. Local variations in the epidemiology, microbiology, and outcome of necrotizing soft-tissue infections: a multicenter study. Am J Surg. 2011; 202:139–145.
Article
54. Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J. 1999; 18:1096–1100.
Article
55. Mulla ZD, Leaverton PE, Wiersma ST. Invasive group A streptococcal infections in Florida. South Med J. 2003; 96:968–973.
Article
56. Ardanuy C, Domenech A, Rolo D, Calatayud L, Tubau F, Ayats J, Martín R, Liñares J. Molecular characterization of macrolide- and multidrug-resistant Streptococcus pyogenes isolated from adult patients in Barcelona, Spain (1993-2008). J Antimicrob Chemother. 2010; 65:634–643.
Article
57. Wong CH, Chang HC, Pasupathy S, Khin LW, Tan JL, Low CO. Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am. 2003; 85-A:1454–1460.
58. Elliott DC, Kufera JA, Myers RA. Necrotizing soft tissue infections. Risk factors for mortality and strategies for management. Ann Surg. 1996; 224:672–683.
59. Voros D, Pissiotis C, Georgantas D, Katsaragakis S, Antoniou S, Papadimitriou J. Role of early and extensive surgery in the treatment of severe necrotizing soft tissue infection. Br J Surg. 1993; 80:1190–1191.
Article
60. Darabi K, Abdel-Wahab O, Dzik WH. Current usage of intravenous immune globulin and the rationale behind it: the Massachusetts General Hospital data and a review of the literature. Transfusion. 2006; 46:741–753.
Article
61. Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O'Rourke K, Talbot J, Low DE. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis. 1999; 28:800–807.
Article
62. Norrby-Teglund A, Ihendyane N, Darenberg J. Intravenous immunoglobulin adjunctive therapy in sepsis, with special emphasis on severe invasive group A streptococcal infections. Scand J Infect Dis. 2003; 35:683–689.
Article
63. Darenberg J, Ihendyane N, Sjölin J, Aufwerber E, Haidl S, Follin P, Andersson J, Norrby-Teglund A. StreptIg Study Group. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003; 37:333–340.
Article
64. Kim T, Park SY, Gwak YG, Choi SH. Jung J, You SN, Hong H-L, Kim YK, Park SY, Song EH, Park K-H, Cho OH, Choi SH, and the Korean SSTI (Skin and Soft Tissue Infection) Study Group. A multicenter study of clinical characteristics and microbial etiology in community-onset pyomyositis in Korea. [abstract]. Int J Antimicrob Agents. 2017; 50:Suppl 1. S136.
65. Yu JS, Habib P. MR imaging of urgent inflammatory and infectious conditions affecting the soft tissues of the musculoskeletal system. Emerg Radiol. 2009; 16:267–276.
Article
66. Turecki MB, Taljanovic MS, Stubbs AY, Graham AR, Holden DA, Hunter TB, Rogers LF. Imaging of musculoskeletal soft tissue infections. Skeletal Radiol. 2010; 39:957–971.
Article
67. Crum NF. Bacterial pyomyositis in the United States. Am J Med. 2004; 117:420–428.
Article
68. Chiu SK, Lin JC, Wang NC, Peng MY, Chang FY. Impact of underlying diseases on the clinical characteristics and outcome of primary pyomyositis. J Microbiol Immunol Infect. 2008; 41:286–293.
69. Faraklas I, Stoddard GJ, Neumayer LA, Cochran A. Development and validation of a necrotizing soft-tissue infection mortality risk calculator using NSQIP. J Am Coll Surg. 2013; 217:153–160.e3. discussion 160-1.
Article
70. Bryant AE, Stevens DL. Clostridial myonecrosis: new insights in pathogenesis and management. Curr Infect Dis Rep. 2010; 12:383–391.
Article
71. Stevens DL, Maier KA, Laine BM, Mitten JE. Comparison of clindamycin, rifampin, tetracycline, metronidazole, and penicillin for efficacy in prevention of experimental gas gangrene due to Clostridium perfringens. J Infect Dis. 1987; 155:220–228.
Article
72. Stevens DL, Laine BM, Mitten JE. Comparison of single and combination antimicrobial agents for prevention of experimental gas gangrene caused by Clostridium perfringens. Antimicrob Agents Chemother. 1987; 31:312–316.
Article
73. Broder J, Jerrard D, Olshaker J, Witting M. Low risk of infection in selected human bites treated without antibiotics. Am J Emerg Med. 2004; 22:10–13.
Article
74. Medeiros I, Saconato H. Antibiotic prophylaxis for mammalian bites. Cochrane Database Syst Rev. 2001; CD001738.
Article
75. Zubowicz VN, Gravier M. Management of early human bites of the hand: a prospective randomized study. Plast Reconstr Surg. 1991; 88:111–114.
76. Cummings P. Antibiotics to prevent infection in patients with dog bite wounds: a meta-analysis of randomized trials. Ann Emerg Med. 1994; 23:535–540.
Article
77. Callaham M. Prophylactic antibiotics in common dog bite wounds: a controlled study. Ann Emerg Med. 1980; 9:410–414.
Article
78. Dire DJ. Emergency management of dog and cat bite wounds. Emerg Med Clin North Am. 1992; 10:719–736.
Article
79. Elenbaas RM, McNabney WK, Robinson WA. Prophylactic oxacillin in dog bite wounds. Ann Emerg Med. 1982; 11:248–251.
Article
80. Dire DJ, Hogan DE, Walker JS. Prophylactic oral antibiotics for low-risk dog bite wounds. Pediatr Emerg Care. 1992; 8:194–199.
Article
81. Abrahamian FM, Goldstein EJ. Microbiology of animal bite wound infections. Clin Microbiol Rev. 2011; 24:231–246.
Article
82. Goldstein EJ, Citron DM, Wield B, Blachman U, Sutter VL, Miller TA, Finegold SM. Bacteriology of human and animal bite wounds. J Clin Microbiol. 1978; 8:667–672.
Article
83. Goldstein EJ, Citron DM. Comparative activities of cefuroxime, amoxicillin-clavulanic acid, ciprofloxacin, enoxacin, and ofloxacin against aerobic and anaerobic bacteria isolated from bite wounds. Antimicrob Agents Chemother. 1988; 32:1143–1148.
Article
84. Goldstein EJ, Citron DM, Finegold SM. Dog bite wounds and infection: a prospective clinical study. Ann Emerg Med. 1980; 9:508–512.
Article
85. Goldstein EJ, Citron DM, Richwald GA. Lack of in vitro efficacy of oral forms of certain cephalosporins, erythromycin, and oxacillin against Pasteurella multocida. Antimicrob Agents Chemother. 1988; 32:213–215.
Article
86. Stevens DL, Higbee JW, Oberhofer TR, Everett ED. Antibiotic susceptibilities of human isolates of Pasteurella multocida. Antimicrob Agents Chemother. 1979; 16:322–324.
Article
87. Muguti GI, Dixon MS. Tetanus following human bite. Br J Plast Surg. 1992; 45:614–615.
Article
88. Talan DA, Citron DM, Abrahamian FM, Moran GJ, Goldstein EJ. Bacteriologic analysis of infected dog and cat bites. Emergency Medicine Animal Bite Infection Study Group. N Engl J Med. 1999; 340:85–92.
Article
89. Kroger AT, Atkinson WL, Marcuse EK, Pickering LK; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006; 55:1–48.
90. Korean Centers for Disease Control and Prevention (KCDC). Guideline for rabies control 2017. Accessed 22 December, 2017. Available at: http://www.cdc.go.kr/CDC/notice/CdcKrTogether0302.jsp?menuIds=HOME001-MNU1154-U0005-MNU0088&cid=75073.
91. Rupprecht CE, Briggs D, Brown CM, Franka R, Katz SL, Kerr HD, Lett SM, Levis R, Meltzer MI, Schaffner W, Cieslak PR. Centers for Disease Control and Prevention (CDC). Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices. MMWR Recomm Rep. 2010; 59:1–9.
92. Zook EG, Miller M, Van Beek AL, Wavak P. Successful treatment protocol for canine fang injuries. J Trauma. 1980; 20:243–247.
Article
93. Schultz RC, McMaster WC. The treatment of dog bite injuries, especially those of the face. Plast Reconstr Surg. 1972; 49:494–500.
Article
94. Chen E, Hornig S, Shepherd SM, Hollander JE. Primary closure of mammalian bites. Acad Emerg Med. 2000; 7:157–161.
Article
95. Maimaris C, Quinton DN. Dog-bite lacerations: a controlled trial of primary wound closure. Arch Emerg Med. 1988; 5:156–161.
Article
Full Text Links
  • IC
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr